HIGHLIGHTS
- who: Honghai Guo from the (CAMS), China Zhejiang University, China have published the research work: Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial, in the Journal: (JOURNAL)
- what: The study showed the short-term benefit of adding sintilimab to neoadjuvant chemotherapy in patients with LAGC. In contrast to the three-cycle neoadjuvant regimen explored in this study, the authors explored the efficacy and safety of four-cycle neoadjuvant therapy with preoperative sintilimab, oxaliplatin, and capecitabine, which is . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.